ScripThe latest paper published by a research team at the National Cancer Center of China serves as a timely reminder that cancer, rather than COVID-19, remains the top public health concern in the country
ScripOn 25 November, China's National Medical Products Administration granted a green light to envafolimab (KN035), the first humanized anti-PD-L1 single domain and human IgG1 Fc antibody formulated for su